Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?

BioMetals

Volumn 30, Issue 1, 2017, Pages

  Jodeiri Farshbaf, Mohammad ^a   Ghaedi, Kamran ^b,c  

^a NEW MEXICO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

Alzheimer s disease; Cancer; Iron; mTOR; Neuroinflammation; Parkinson s disease

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; DEGENERATIVE DISEASE; DNA DAMAGE; DRUG TARGETING; FENTON REACTION; HEMOSTASIS; HUMAN; IRON DEFICIENCY; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIPID PEROXIDATION; MALIGNANT NEOPLASM; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; RESPIRATORY CHAIN; REVIEW; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HUNTINGTON CHOREA; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; HUMANS; HUNTINGTON DISEASE; IRON; LIPID PEROXIDATION; NEOPLASMS; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84995467891     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-016-9981-x     Document Type: Review

References (165)

1. Aliev G, Palacios HH, Lipsitt AE, Fischbach K, Lamb BT, Obrenovich ME, Morales L, Gasimov E, Bragin V (2009) Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res 16(3):293–305
2. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol 163:591–607
3. Andersen HH, Johnsen KB, Moos T (2014) Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol Life Sci 71(9):1607–1622
4. Armengol G, Rojo F, Castellví J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, y Cajal SR (2007) 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 67(16):7551–7555
5. Arredondo M, Tapia V, Rojas A, Aguirre P, Reyes F, Marzolo MP, Núñez MT (2006) Apical distribution of HFE-beta2-microglobulin is associated with inhibition of apical iron uptake in intestinal epithelia cells. Biometals 19(4):379–388
6. Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B (2002) Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol 59(11):1793–1799
7. Babior BM (1999) NADPH oxidase: an update. Blood 93(5):1464–1476
8. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT (2010) Novel drug targets based on metallobiology of Alzheimer’s disease. Expert Opin Ther Targets 14(11):1177–1197
9. Barcia C, de Pablos V, Bautista-Hernández V, Sánchez-Bahillo A, Bernal I, Fernández-Villalba E, Martín J, Bañón R, Fernández-Barreiro A, Herrero MT (2005) Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 11(7):435–439
10. Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi A (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92(15):1252–1259
11. Bar-Peled L, Sabatini DM (2014) Regulation of mTORC1 by amino acids. Trends Cell Biol 24(7):400–406
12. Bayeva M, Khechaduri A, Puig S, Chang HC, Patial S, Blackshear PJ, Ardehali H (2012) mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab 16(5):645–657
13. Boehrer S, Adès L, Galluzzi L, Tajeddine N, Tailler M, Gardin C, de Botton S, Fenaux P, Kroemer G (2008) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 76:1417–1425
14. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172(1–2):151–154
15. Bové J, Martínez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12(8):437–452
16. Breuer W, Hershko C, Cabantchik ZI (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 23:185–192
17. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, Dolan KG, Haile DJ, Beard JL, Connor JR (2001) Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 66(6):1198–1207
18. Caccamo A, Magrì A, Medina DX, Wisely EV, López-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies. Aging Cell 12:370–380
19. Cai Z, Chen G, He W, Xiao M, Yan LJ (2015) Activation of mTOR: a culprit of Alzheimer’s disease? Neuropsychiatr Dis Treat 9(11):1015–1030
20. Cairo G, Recalcati S, Pietrangelo A, Minotti G (2002) The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32(12):1237–1243
21. Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA (2004) Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 63(8):821–830
22. Cavadini P, Biasiotto G, Poli M, Levi S, Verardi R, Zanella I, Derosas M, Ingrassia R, Corrado M, Arosio P (2007) RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 109(8):3552–3559
23. Chege PM, McColl G (2014) Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson’s disease. Front Aging Neurosci 19(6):89
24. Chen YC, Wu YT, Wei YH (2015) Depletion of mitoferrins leads to mitochondrial dysfunction and impairment of adipogenic differentiation in 3T3-L1 preadipocytes. Free Radic Res 49(11):1285–1295
25. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT (2010) Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 285(41):31217–31232
26. Choi DH, Cristóvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim YS (2012) NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson’s disease. Antioxid Redox Signal 16(10):1033–1045
27. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K (2010) Mammalian target of rapamycin: hitting the bull’s-eye for neurological disorders. Oxid Med Cell Longev 3(6):374–391
28. Ciechanover A, Kwon YT (2015) Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med 13(47):e147
29. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, McElwaine JN, Hughes TA (2009) Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100(9):1393–1399
30. Corsi B, Cozzi A, Arosio P, Drysdale J, Santambrogio P, Campanella A, Biasiotto G, Albertini A, Levi S (2002) Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem 277(25):22430–22437
31. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292–1295
32. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J (2001) Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28(4):350–354
33. Dawson VL, Dawson TM (1998) Nitric oxide in neurodegeneration. Prog Brain Res 118:215–229
34. De Arriba Zerpa GA, Saleh MC, Fernández PM, Guillou F, de Espinosa los Monteros A, de Vellis J, Zakin MM, Baron B (2000) Alternative splicing prevents transferrin secretion during differentiation of a human oligodendrocyte cell line. J Neurosci Res 61(4):388–395
35. De Domenico I, McVey Ward D, Kaplan J (2008) Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 9(1):72–81
36. Devi L, Ohno M (2010) Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS ONE 5(9):e12974
37. Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 11(11):812–823
38. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI (2000) Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403(6771):776–781
39. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1(3):191–200
40. Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire HG, Kang J, Müller-Hill B, Masters CL, Beyreuther K (1988) Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer’s disease. EMBO J 7(4):949–957
41. Eaton JW, Qian M (2002) Molecular bases of cellular iron toxicity. Free Radic Biol Med 32(9):833–840
42. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ (2008) Reversal of learning deficits in a Tsc2 ± mouse model of tuberous sclerosis. Nat Med 14(8):843–848
43. Eisenstein RS, Ross KL (2003) Novel roles for iron regulatory proteins in the adaptive response to iron deficiency. J Nutr 133(5 Suppl 1):1510S–1516S
44. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem 86(5):1142–1148
45. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 16(4):47
46. Fredenburg AM, Sethi RK, Allen DD, Yokel RA (1996) The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 108(3):191–199
47. Frederick C, Ando K, Leroy K, Héraud C, Suain V, Buée L, Brion JP (2014) Rapamycin ester analog CCI-779/temsirolimus alleviates tau pathology and improves motor deficit in mutant tau Transgenic mice. J Alzheimers Dis 44:1145–1156
48. Fretham SJ, Carlson ES, Georgieff MK (2011) The role of iron in learning and memory. Adv Nutr 2(2):112–121
49. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16(18):1865–1870
50. Friedlich AL, Tanzi RE, Rogers JT (2007) The 5′-untranslated region of Parkinson’s disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 12(3):222–223
51. Galvez T, Teruel MN, Heo WD, Jones JT, Kim ML, Liou J, Myers JW, Meyer T (2007) siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake. Genome Biol 8(7):R142
52. Gao G, Chang YZ (2014) Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Front Pharmacol 17(5):19
53. Gingras AC, Kennedy SG, O’Leary MA, Sonenberg N, Hay N (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12(4):502–513
54. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13:1422–1437
55. Gogvadze V, Walter PB, Ames BN (2003) The role of Fe2 + -induced lipid peroxidation in the initiation of the mitochondrial permeability transition. Arch Biochem Biophys 414(2):255–260
56. Graber TE, McCamphill PK, Sossin WS (2013) A recollection of mTOR signaling in learning and memory. Learn Mem 20:518–530
57. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F, Wang C, Wolvetang E, Vazquez-Martin A, Zhang J (2013) Autophagy in stem cells. Autophagy 9(6):830–849
58. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388(6641):482–488
59. Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2(5):a006270
60. Halestrap AP, Kerr PM, Javadov S, Woodfield KY (1998) Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1366(1–2):79–94
61. Hare D, Ayton S, Bush A, Lei P (2013) A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 18(5):34
62. Hentze MW, Kühn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 93(16):8175–8182
63. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117(3):285–297
64. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y (2010) Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer 70(1):94–102
65. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27(18):2432–2443
66. Jiang ZG, Lebowitz MS, Ghanbari HA (2006) Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent. CNS Drug Rev 12(1):77–90
67. Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ, Gao L, Qin H, Zhang YD, Tan L (2014) Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer’s disease. Pharmacol Res 81:54–63
68. Jodeiri Farshbaf M, Ghaedi K, Megraw TL, Curtiss J, Shirani Faradonbeh M, Vaziri P, Nasr-Esfahani MH (2016a) Does PGC1α/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders? Neuromol Med 18(1):1–15
69. Jodeiri Farshbaf M, Forouzanfar M, Ghaedi K, Kiani-Esfahani A, Peymani M, Shoaraye Nejati A, Izadi T, Karbalaie K, Noorbakhshnia M, Rahgozar S, Baharvand H, Nasr-Esfahani MH (2016b) Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment. Mol Cell Biochem 420(1–2):29–42
70. Kim YC, Guan KL (2015) mTOR: a pharmacologic target for autophagy regulation. J Clin Invest 125:25–32
71. Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH (1997) Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol 10(11):1285–1292
72. Klus P, Cirillo D, Botta Orfila T, Gaetano Tartaglia G (2015) Neurodegeneration and cancer: where the disorder prevails. Sci Rep 5:15390
73. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441(7095):880–884
74. Komatsu M, Wang QJ, Holstein GR, Friedrich VL Jr, Iwata J, Kominami E, Chait BT, Tanaka K, Yue Z (2007) Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci USA 104(36):14489–14494
75. Kumari U, Tan EK (2009) LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J 276:6455–6463
76. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J Neurochem 94:215–225
77. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293
78. Lawen A, Lane DJR (2013) Mammalian iron homeostasis in health and disease: uptake, storage, transport, andmolecular mechanisms of action. Antioxid Redox Signal 18(18):2473–2507
79. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141(7):1146–1158
80. Levi S, Corsi B, Bosisio M, Invernizzi R, Volz A, Sanford D, Arosio P, Drysdale J (2001) A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 276(27):24437–24440
81. Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, Yang W, Le W (2013) Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer’s disease. Curr Alzheimer Res 10(4):433–441
82. Li CY, Li X, Liu SF, Qu WS, Wang W, Tian DS (2015) Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen-glucose deprivation and reoxygenation. Neurochem Int 83–84:9–18
83. Liddell JR, Obando D, Liu J, Ganio G, Volitakis I, Mok SS, Crouch PJ, White AR, Codd R (2013) Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radic Biol Med 60:147–156
84. Lil R (2009) Function and biogenesis of iron–Sulphur proteins. Nature 460(7257):831–838
85. Liu Y, Su Y, Wang J, Sun S, Wang T, Qiao X, Run X, Li H, Liang Z (2013) Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int 62(4):458–467
86. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell 11(2):326–335
87. Mello-Filho AC, Meneghini R (1991) Iron is the intracellular metal involved in the production of DNA damage by oxygen radicals. Mutat Res 251(1):109–113
88. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763–777
89. Mikhael M, Kim SF, Schranzhofer M, Soe-Lin S, Sheftel AD, Mullner EW, Ponka P (2006) Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide. FEBS J 273(16):3828–3836
90. Moos T, Morgan EH (2004) The metabolism of neuronal iron and its pathogenic role in neurological disease. Ann N Y Acad Sci 1012:14–26
91. Morris CM, Candy JM, Omar S, Bloxham CA, Edwardson JA (1994) Transferrin receptors in the parkinsonian midbrain. Neuropathol Appl Neurobiol 20(5):468–472
92. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26(3):349–354
93. Muhoberac BB, Vidal R (2013) Abnormal iron homeostasis and neurodegeneration. Front Aging Neurosci 30(5):32
94. Nie G, Sheftel AD, Kim SF, Ponka P (2005) Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 105(5):2161–2167
95. Noda NN, Inagaki F (2015) Mechanisms of Autophagy. Annu Rev Biophys 44:101–122
96. Noh KM, Koh JY (2000) Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 20(23):RC111
97. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS (2008) Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 110(3):477–483
98. Oddo S (2012) The role of mTOR signaling in Alzheimer disease. Front Biosci 4:941–952
99. Oh S, Shin PK, Chung J (2015) Effects of developmental iron deficiency and post-weaning iron repletion on the levels of iron transporter proteins in rats. Nutr Res Pract 9(6):913–918
100. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K (2009) The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 100(5):970–977
101. Oshiro S, Nakamura Y, Ishige R, Hori M, Nakajima H, Gahl WA (1994) Reduction site of transferrin-dependent and transferrin-independent iron in cultured human fibroblasts”. J Biochem 115(5):849–852
102. Oshiro S, Kawahara M, Mika S, Muramoto K, Kobayashi K, Ishige R, Nozawa K, Hori M, Yung C, Kitajima S, Kuroda Y (1998) Aluminum taken up by transferrin-independent iron uptake affects the iron metabolism in rat cortical cells. J Biochem 123(1):42–46
103. Oshiro S, Morioka MS, Kikuchi M (2011) Dysregulation of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. doi:10.1155/2011/378278
104. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R, Hugon J (2006) Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 22(4):320–326
105. Pandolfo M (2006) Iron and friedreich ataxia. J Neural Transm Suppl 70:143–146
106. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11):2257–2267
107. Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J (2009) Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol 29(4):1007–1016
108. Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32(11):1959–1972
109. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C (2008) Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA 105(4):1347–1352
110. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K (2003) Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer’s disease. Am J Pathol 163(3):845–858
111. Pei JJ, Sjögren M, Winblad B (2008) Neurofibrillary degeneration in Alzheimer’s disease: from molecular mechanisms to identification of drug targets. Curr Opin Psychiatry 21(6):555–561
112. Pierce A, Podlutskaya N, Halloran JJ, Hussong SA, Lin PY, Burbank R, Hart MJ, Galvan V (2013) Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer’s-like deficits in mice modeling the disease. J Neurochem 124(6):880–893
113. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6(12):e1001257
114. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM (2011) mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res. 24(1):254–257
115. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 80(2):168–176
116. Przedborski S, Vila M, Jackson-Lewis V (2003) Neurodegeneration: what is it and where are we? J Clin Investig 111:3–10
117. Rao R, Tkac I, Townsend EL, Gruetter R, Georgieff MK (2003) Perinatal iron deficiency alters the neurochemical profile of the developing rat hippocampus. J Nutr 133(10):3215–3221
118. Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC (2006) Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15(7):1209–1216
119. Remarque EJ, Bollen EL, Weverling-Rijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG (2001) Patients with Alzheimer’s disease display a pro-inflammatory phenotype. Exp Gerontol 36(1):171–176
120. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P (1997) Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. Nat Genet 17(2):215–217
121. Rouault TA, Tong WH (2008) Iron–sulfur cluster biogenesis and human disease. Trends Genet 24(8):398–407
122. Rubinsztein DC, Marino G, Kroemer G (2011) Autophagy and aging. Cell 146:682–695
123. Santambrogio P, Biasiotto G, Sanvito F, Olivieri S, Arosio P, Levi S (2007) Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem 55(11):1129–1137
124. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14):1296–1302
125. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101
126. Schmucker S, Puccio H (2010) Understanding the molecular mechanisms of Friedreich’s ataxia to develop therapeutic approaches. Hum Mol Genet 19(R1):R103–R110
127. Seo AY, Xu J, Servais S, Hofer T, Marzetti E, Wohlgemuth SE, Knutson MD, Chung HY, Leeuwenburgh C (2008) Mitochondrial iron accumulation with age and functional consequences. Aging Cell 7(5):706–716
128. Shastri A, Bonifati DM, Kishore U (2013) Innate immunity and neuroinflammation. Mediators Inflamm 2013:342931
129. Sheftel AD, Zhang AS, Brown C, Shirihai OS, Ponka P (2007) Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 110(1):125–132
130. Shen HM, Mizushima N (2014) At the end of the autophagic road: an emerging understanding of lysosomal functions in autophagy. Trends Biochem Sci 39(2):61–71
131. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 17(5):761–766
132. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760
133. Shoshan-Barmatz V, Mizrachi D (2012) VDAC1: from structure to cancer therapy. Front Oncol 29(2):164
134. Sochaski MA, Bartfay WJ, Thorpe SR, Baynes JW, Bartfay E, Lehotay DC, Liu PP (2002) Lipid peroxidation and protein modification in a mouse model of chronic iron overload. Metabolism 51(5):645–651
135. Soriano S, Lu DC, Chandra S, Pietrzik CU, Koo EH (2001) The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases. J Biol Chem 276(31):29045–29050
136. Steffens GC, Biewald R, Buse G (1987) Cytochrome c oxidase is a three-copper, two-heme-A protein. Eur J Biochem 164(2):295–300
137. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1(1):14
138. Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L (2008) Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem 106(1):24–36
139. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274(34):24142–24146
140. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12(9):1129–1135
141. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 99:467–472
142. Theil EC (2004) Iron, ferritin, and nutrition. Annu Rev Nutr 24:327–343
143. Thelander L, Gräslund A (1983) Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J Biol Chem 258(7):4063–4066
144. Tribl F, Asan E, Arzberger T, Tatschner T, Langenfeld E, Meyer HE, Bringmann G, Riederer P, Gerlach M, Marcus K (2009) Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol Cell Proteomics 8(8):1832–1838
145. Troca-Marin JA, Alves-Sampaio A, Montesinos ML (2012) Deregulated mTOR-mediated translation in intellectual disability. Prog Neurobiol 96:268–282
146. Uversky VN (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21(2):211–234
147. Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4:365–375
148. Wang X, Proud CG (2006) The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 21:362–369
149. Wang L, Lawrence JC Jr, Sturgill TW, Harris TE (2009) Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem 284(22):14693–14697
150. Wang L, Yang H, Zhao S, Sato H, Konishi Y, Beach TG, Abdelalim EM, Bisem NJ, Tooyama I (2011) Expression and localization of mitochondrial ferritin mRNA in Alzheimer’s disease cerebral cortex. PLoS ONE 6(7):e22325
151. White AR, Kanninen KM, Crouch PJ (2015) Editorial: metals and neurodegeneration: restoring the balance. Front Aging Neurosci 2(7):127
152. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC (2006) Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 76:89–101
153. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, Zon LI (2005) Deficiency of glutaredoxin 5 reveals Fe–S clusters are required for vertebrate haem synthesis. Nature 436(7053):1035–1039
154. Wolff NA, Ghio AJ, Garrick LM, Garrick MD, Zhao L, Fenton RA, Thevenod F (2014a) Evidence for mitochondrial localization of divalent metal transporter 1 (DMT1). FASEB J 28(5):2134–2145
155. Wolff NA, Garrick LM, Zhao L, Garrick MD, Thévenod F (2014b) Mitochondria represent another locale for the divalent metal transporter 1 (DMT1). Channels (Austin) 8(5):458–466
156. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci USA 100(10):6145–6150
157. Wu WS, Zhao YS, Shi ZH, Chang SY, Nie GJ, Duan XL, Zhao SM, Wu Q, Yang ZL, Zhao BL, Chang YZ (2013) Mitochondrial ferritin attenuates β-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways. Antioxid Redox Signal 18(2):158–169
158. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484
159. Yang Z, Klionsky DJ (2010) Eaten alive: a history of macroautophagy. Nat Cell Biol 12(9):814–822
160. Yang H, Yang M, Guan H, Liu Z, Zhao S, Takeuchi S, Yanagisawa D, Tooyama I (2013) Mitochondrial ferritin in neurodegenerative diseases. Neurosci Res 77(1–2):1–7
161. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease. Neurotox Res 19(1):63–72
162. Zhou XW, Tanila H, Pei JJ (2008) Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction. FEBS Lett 582:159–164
163. Zhou L, Huang Y, Li J, Wang Z (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27(2):255–261
164. Zoccarato F, Toscano P, Alexandre A (2005) Dopamine-derived dopaminochrome promotes H2O2 release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 280(16):15587–15594
165. Zucca FA, Bellei C, Giannelli S, Terreni MR, Gallorini M, Rizzio E, Pezzoli G, Albertini A, Zecca L (2006) Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna) 113(6):757–767